Korean J Med.  2015 Jun;88(6):643-646. 10.3904/kjm.2015.88.6.643.

Treatment of Hepatitis C in Special Conditions: Liver Cirrhosis

• Gwak GY

• KMID: 2269070
• DOI: http://doi.org/10.3904/kjm.2015.88.6.643

Abstract

Acquiring a sustained virological response (SVR) in patients with cirrhosis or advanced hepatic fibrosis reduces liver disease-related mortality and the incidence of hepatocellular carcinoma. However, the SVR rate of the current standard of care, which is combination therapy with peg-interferon-alpha and ribavirin, is significantly lower, and treatment-related complications occur more frequently in patients with cirrhosis. Thus, antiviral treatment should be individualized in this population. This review highlights the issues associated with anti-hepatitis C virus treatment in patients with compensated and decompensated cirrhosis.

Keyword

Hepatitis C; Cirrhosis; SVR; Antiviral therapy

MeSH Terms

Carcinoma, Hepatocellular
Fibrosis
Hepatitis C*
Humans
Incidence
Liver
Liver Cirrhosis*
Mortality
Ribavirin
Standard of Care
Ribavirin